Log in

NASDAQ:SPNESeaSpine Stock Price, Forecast & News

-0.20 (-1.84 %)
(As of 06/1/2020 04:00 PM ET)
Today's Range
Now: $10.65
50-Day Range
MA: $10.11
52-Week Range
Now: $10.65
Volume90,400 shs
Average Volume232,212 shs
Market Capitalization$290.15 million
P/E RatioN/A
Dividend YieldN/A
SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and DBM. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in degenerative, minimally invasive, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical regions of the spine. The company was incorporated in 2015 and is headquartered in Carlsbad, California.
Read More
SeaSpine logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.54 out of 5 stars

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:SPNE



Sales & Book Value

Annual Sales$159.08 million
Book Value$5.74 per share


Net Income$-39,280,000.00


Market Cap$290.15 million
Next Earnings Date8/6/2020 (Estimated)

Receive SPNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SPNE and its competitors with MarketBeat's FREE daily newsletter.

SeaSpine (NASDAQ:SPNE) Frequently Asked Questions

How has SeaSpine's stock been impacted by COVID-19 (Coronavirus)?

SeaSpine's stock was trading at $10.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, SPNE shares have decreased by 0.7% and is now trading at $10.65. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of SeaSpine?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for SeaSpine.

When is SeaSpine's next earnings date?

SeaSpine is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for SeaSpine.

How were SeaSpine's earnings last quarter?

SeaSpine Holdings Corp (NASDAQ:SPNE) announced its quarterly earnings results on Wednesday, May, 6th. The medical equipment provider reported ($0.43) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.37) by $0.06. The medical equipment provider earned $36.11 million during the quarter, compared to analyst estimates of $35.89 million. SeaSpine had a negative return on equity of 27.09% and a negative net margin of 26.93%. View SeaSpine's earnings history.

What guidance has SeaSpine issued on next quarter's earnings?

SeaSpine issued an update on its first quarter 2020 Pre-Market earnings guidance on Monday, April, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $35.8-36.2 million, compared to the consensus revenue estimate of $40.13 million.

What price target have analysts set for SPNE?

4 analysts have issued 12-month price objectives for SeaSpine's shares. Their forecasts range from $10.00 to $21.00. On average, they expect SeaSpine's stock price to reach $16.50 in the next twelve months. This suggests a possible upside of 54.9% from the stock's current price. View analysts' price targets for SeaSpine.

Has SeaSpine been receiving favorable news coverage?

Media headlines about SPNE stock have been trending very positive recently, according to InfoTrie Sentiment. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. SeaSpine earned a media sentiment score of 3.5 on InfoTrie's scale. They also gave news headlines about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutSeaSpine.

Who are some of SeaSpine's key competitors?

What other stocks do shareholders of SeaSpine own?

Who are SeaSpine's key executives?

SeaSpine's management team includes the following people:
  • Mr. Keith C. Valentine, Pres, CEO & Director (Age 51)
  • Mr. John J. Bostjancic, Sr. VP, CFO & Treasurer (Age 48)
  • Mr. Patrick L. Keran, VP, Gen. Counsel & Corp. Sec. (Age 47)
  • Carrie Mendivil, Head of Investor Relations
  • Mr. John J. Winge, VP of Sales (Age 52)

What is SeaSpine's stock symbol?

SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."

Who are SeaSpine's major shareholders?

SeaSpine's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.78%), Driehaus Capital Management LLC (5.03%), Polar Asset Management Partners Inc. (3.56%), The Manufacturers Life Insurance Company (1.93%), Silvercrest Asset Management Group LLC (1.89%) and JPMorgan Chase & Co. (1.42%). Company insiders that own SeaSpine stock include John B Henneman III, Keith Valentine, Richard E Caruso and Stuart Essig. View institutional ownership trends for SeaSpine.

Which institutional investors are selling SeaSpine stock?

SPNE stock was sold by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., The Manufacturers Life Insurance Company , Parametric Portfolio Associates LLC, Monarch Partners Asset Management LLC, WINTON GROUP Ltd, Falcon Point Capital LLC, UBS Group AG, and GSA Capital Partners LLP. View insider buying and selling activity for SeaSpine.

Which institutional investors are buying SeaSpine stock?

SPNE stock was bought by a variety of institutional investors in the last quarter, including Driehaus Capital Management LLC, Polar Asset Management Partners Inc., Silvercrest Asset Management Group LLC, BlackRock Inc., JPMorgan Chase & Co., Emerald Advisers LLC, Stonepine Capital Management LLC, and Emerald Mutual Fund Advisers Trust. View insider buying and selling activity for SeaSpine.

How do I buy shares of SeaSpine?

Shares of SPNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is SeaSpine's stock price today?

One share of SPNE stock can currently be purchased for approximately $10.65.

How big of a company is SeaSpine?

SeaSpine has a market capitalization of $290.15 million and generates $159.08 million in revenue each year. The medical equipment provider earns $-39,280,000.00 in net income (profit) each year or ($2.07) on an earnings per share basis. SeaSpine employs 361 workers across the globe.

What is SeaSpine's official website?

The official website for SeaSpine is www.seaspine.com.

How can I contact SeaSpine?

SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-727-8399 or via email at [email protected]

This page was last updated on 6/2/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.